Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Target Price at $10.33

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) has earned an average rating of "Buy" from the five analysts that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $10.33.

Several brokerages have recently weighed in on CRBU. Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Citigroup lowered their target price on Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Wednesday, March 19th.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU traded down $0.08 during midday trading on Friday, reaching $0.88. 1,247,059 shares of the company's stock were exchanged, compared to its average volume of 1,593,705. The firm's 50 day simple moving average is $1.27 and its two-hundred day simple moving average is $1.72. Caribou Biosciences has a fifty-two week low of $0.88 and a fifty-two week high of $5.50. The stock has a market cap of $81.95 million, a price-to-earnings ratio of -0.53 and a beta of 2.34.

Remove Ads

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Equities research analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Caribou Biosciences

A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company's stock valued at $3,980,000 after purchasing an additional 124,782 shares in the last quarter. Barclays PLC boosted its holdings in Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company's stock valued at $255,000 after acquiring an additional 71,463 shares during the last quarter. US Bancorp DE grew its position in shares of Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after buying an additional 26,467 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Caribou Biosciences by 19.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company's stock valued at $1,449,000 after acquiring an additional 118,325 shares during the last quarter. Finally, FMR LLC lifted its stake in Caribou Biosciences by 7.4% in the third quarter. FMR LLC now owns 1,581,493 shares of the company's stock valued at $3,100,000 after buying an additional 109,606 shares during the period. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.